文献速递骨质疏松与代谢性骨病创伤骨科

被诊断为骨质疏松的女性Medicare受益者的药物持续使用与骨折风险

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
PubMed 文献 · Osteoporos Int · 2018-07-18

本研究基于2009至2012年Medicare理赔数据,纳入294,369例开始骨质疏松药物治疗的女性Medicare受益者,比较持续用药(连续≥1年无≥60天间隔)与非持续用药者的脆性骨折风险及医疗费用。持续用药与骨折风险降低及随访期总医疗费用显著降低相关,多种分析方法结果一致。

要点

  • 持续用药者骨折发生率从用药前16.2/100患者年降至用药后4.1/100患者年。
  • 非持续用药者骨折发生率从用药前19.0/100患者年降至用药后7.3/100患者年。
  • 调整后骨折率比持续用药者为0.284,非持续用药者为0.411,两者比值为0.692(p<0.0001)。

核心结论

  • 持续使用骨质疏松药物与骨折风险降低及总医疗费用显著降低相关。
  • 支付方和患者可从提高药物持续性的干预中获益。

研究设计与样本

  • 利用2009至2012年Medicare理赔数据,纳入2009年1月1日至2011年6月30日开始骨质疏松药物治疗的被诊断为骨质疏松的女性Medicare受益者。
  • 持续用药定义为连续使用1年或更长时间且无≥60天间隔。
  • 采用泊松回归模型在骨折率对数尺度上进行双重差分分析,以用药前1至6个月为用药前期、用药后至18个月为用药后期。
  • 采用类似方法比较总医疗费用,并使用不同的用药前和用药后期进行敏感性分析。

主要发现

  • 共纳入294,369例患者,其中32.9%为持续用药者,67.1%为非持续用药者(连续使用<12个月)。
  • 持续用药者骨折发生率用药前为16.2/100患者年,用药后为4.1/100患者年;非持续用药者相应为19.0/100患者年和7.3/100患者年。
  • 调整后用药后/用药前骨折率比持续用药者为0.284,非持续用药者为0.411;两者比值为0.692(持续 vs 非持续,p<0.0001),提示持续用药者骨折率降低幅度显著更大。
  • 持续用药者的调整后费用比显著更低。
  • 敏感性分析结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We examined the relationship between persistent osteoporosis medication use and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis using Medicare claims, 2009-2012. Persistent use was associated with reduced risk of fracture and significantly lower total health care costs in the follow-up period. Results were consistent using different analytical methods. INTRODUCTION: This study aimed to examine the relationship between medication persistence and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis. METHODS: Elderly female Medicare beneficiaries diagnosed with osteoporosis and initiated on osteoporosis medication January 1, 2009-June 30, 2011, were included. Persistent medication use was defined as continuous use (no gap ≥ 60 days) for 1 year or longer. The key outcome was fragility fracture. A difference-in-difference analysis was performed at the log scale of fracture rate using a Poisson regression model with months 1-6 before medication initiation as the pre-initiation period and up to 18 months after as the post-initiation period. Total health care costs were compared using a similar approach. Sensitivity analyses were conducted using different pre- and post-initiation periods. RESULTS: The study included 294,369 patients; 32.9% were persistent osteoporosis medication users and 67.1% non-persistent (< 12 months continuous use). Fracture incidence rates were 16.2 per 100 patient-years pre-initiation and 4.1 post-initiation for persistent users; corresponding rates for non-persistent users were 19.0 and 7.3 per 100 patient-years. The adjusted post-/pre-initiation fracture rate ratios were 0.284 for persistent and 0.411 for non-persistent users. The ratio of the two rate ratios was 0.692 (persistent vs. non-persistent, p < 0.0001), suggesting a significantly greater fracture rate reduction for persistent users. Adjusted cost ratios were significantly lower for persistent users. Sensitivity analyses results were similar. CONCLUSIONS: Persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total health care costs. Payers and patients would benefit from interventions aimed at improving medication persistence.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Liu J, Guo H, Rai P, et al. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018. PMID: 30022254. doi:10.1007/s00198-018-4630-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。